Our priorities

DACRINs inaugural strategic plan for the 2019 -2021 period is available to download.

Development of DACRINs next strategic plan is underway and is due for release late 2022.

Our outcomes

The following section outlines DACRINs achievements against the 2019-2021 strategic plan.

Priority 1: Establish, support and grow the network

Strategic objectives and activities

  1. To provide sustainable leadership in clinical research activities in the AOD sector in NSW, in collaboration with clinicians, consumers, professional groups and academic researchers and institutions
    • Increase network membership
    • Convene Advisory Group
  2. To promote and facilitate collaboration in inter-disciplinary multisite clinical research and quality improvement activities across AOD services in NSW
    • Implement systems and processes to enable assessment and scale up of research proposals
    • Facilitate interdisciplinary contributions to AOD clinical research and quality improvement

Milestone targets

  • Effective and efficient network operations
  • Number of NSW multisite clinical research studies increased
  • Research recruitment/accrual rates improved
  • Breadth of clinical research and quality improvement questions and methodologies expanded

Achievements

  • Strategic Plan 2019-2021 developed, endorsed, and implemented
  • Established Network governance and Terms of Reference
  • Established and maintained a quarterly Council meeting schedule
  • Links formed with National Centre for Clinical Research on Emerging Drugs (NCCRED), Network of Alcohol and other Drug Agencies (NADA)
  • Full membership of the Australian Clinical Trials Alliance (ACTA) achieved
  • Welcomed 4 new member organisations (CCLHD, ISLHD, JHFMHN, NSLHD)
  • Initiated membership conversations with NADA and WNSWLHD
  • Initiated a collaborative project with NADA and the Ministry of Health to conduct a survey of research capacity across the public and NGO AOD sectors
  • Contributed to national strategies including the Special Commission of Inquiry into the Drug Ice
  • Purchased iPads to allocate to and share with member organisations
  • Invested in training and professional development for member organisations, including an ongoing Good Clinical Practice Train the Trainer program
  • Developed DACRIN's visual identity and marketed DACRIN in wide range of forums and conferences
  • Developed operational systems and processes to facilitate scale up of otherwise localised studies
  • Developed process to facilitate discussion and development of collaborative research funding applications
  • Developed a Project Register showcasing the breadth of collaborative clinical research conducted across member services
  • DACRIN's ClinTrial Refer app established, populated, and maintained

Priority 2: Develop clinical research infrastructure

Strategic objectives and activities

  1. To streamline AOD clinical research governance, including shared policies and procedures across participating services
    • Develop shared governance and operations framework for multisite research
    • Establish shared peer review and stakeholder consultation mechanisms
  2. To develop common research metrics and databases, enabling pooling of AOD clinical data and facilitating meta-analyses, with particular regard to the mounting importance of clinical informatics and data linkage methodologies
    • Formulate standardised approaches to clinical research data and data management
    • Enhance shared understanding of access to and use of clinical data for research purposes

Milestone targets

  • Effective and efficient shared governance and operational systems and processes
  • Capacity for independent peer review and stakeholder consultation
  • Standardised case report forms and comparable data collection across future DACRIN studies
  • Clinical data ownership and access issues documented and disseminated

Achievements

  • Consulted in initiatives of the Australian Commission of Safety and Quality in Health Care including the National Clinical Trials Governance Framework
  • Implemented quarterly DACRIN Coordinator Resource Sharing Days
  • Conducted empirical review of reimbursement practices for AOD research participants
  • Initiated DACRIN Data Project with the objective of standardising data collection across AOD clinical research projects
  • Participated in training and education in use of clinical data for research purposes
  • Established relationship with COQI Program Manager and broader COQI team
  • Obtained membership of joint COQI/NDARC Pragmatic Trials Special Interest Group which seeks to develop a proof of concept 'faux' trial using routine clinical data

Priority 3: Build clinical research and translation capacity

Strategic objectives and activities

  1. To increase clinician, consumer and researcher engagement in AOD clinical research and quality improvement activities, including by facilitating workforce development and other capacity building opportunities
    • Support capacity-building partnerships between clinicians and researchers
    • Facilitate clinician and consumer input into research questions and protocols
  2. To implement strategies that enable clinician and consumer input into the development of research questions and protocols, and enhance the translation of findings into AOD clinical practice
    • Implement feedback process to provide research results to participating clinical services and clients
    • Support member organisations to identify and address barriers to translation of research results

Milestone targets

  • Number of clinicians, consumers and researchers contributing to clinical research increased
  • Clinicians and consumers enabled to pose, review and refine research questions and protocols
  • Clients enabled to consider the personal implications of clinical research
  • Clinical research results implemented in a range of AOD services and settings

Achievements

  • Supported 47 training or professional development opportunities for staff of 10 LHDs/LHNs
  • Drafted Terms of Reference and application form for DACRIN Professional Development Award for AOD Clinical Research.
  • Drafted a model of collaboration and partnership between consumers, clinicians and researchers as the foundation of AOD clinical research and evaluation activities
  • Developed list of peer reviewed publications.
  • Led or contributed to development or updating of multiple State and national clinical practice guidelines, including for depot buprenorphine, alcohol, take home naloxone, toxicology and toxinology, AOD withdrawal, paracetamol poisoning and opioid safety

A printable version of DACRIN strategic plan achievements can also be downloaded.


Current as at: Friday 5 August 2022